Advertisement

Topics

Emergent BioSolutions to buy specialty vaccines company PaxVax for US$ 270 million

09:38 EDT 11 Aug 2018 | PharmaBiz

Emergent BioSolutions Inc has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for an all─cash consideration of

Original Article: Emergent BioSolutions to buy specialty vaccines company PaxVax for US$ 270 million

NEXT ARTICLE

More From BioPortfolio on "Emergent BioSolutions to buy specialty vaccines company PaxVax for US$ 270 million"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...